Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2024-12-27 00:00:00 ET · period of report 2024-12-26 · accession 0001415889-24-030210 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-27 | 2024-12-26 | TVTX | Calvin Sandra | SVP, CAO | M - OptEx | $12.67 | +15.0K | 69.9K | +27% | +$190.1K |
| D | 2024-12-27 | 2024-12-26 | TVTX | Calvin Sandra | SVP, CAO | S - Sale+OE | $17.22 | -15.0K | 54.9K | -21% | -$258.3K |
| D | 2024-12-27 | 2024-12-26 | TVTX | Calvin Sandra | SVP, CAO | M - OptEx | $0.00 | -15.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-26 | M | A | 15,000 | $12.67 | 69,927 | D | — | — | |
| 2 | Common | Common Stock | 2024-12-26 | S | D | 15,000 | $17.22 | 54,927 | D | — | — | (F2) The weighted average sale price for the transaction reported was $17.21856, and the range of prices were between $16.985 and $17.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 3 | Derivative | Employee stock option (right to buy) | 2024-12-26 | M | D | 15,000 | $0.00 | 0 | D | $12.67 · — to 2025-01-02 | 15,000 Common Stock | (F3) The stock option is fully vested and exercisable. |